Platelet-derived microvesicles deliver miR-30e and promote VSMC apoptosis after balloon injury

Li, Zi-Tong; Chen, Yuan-Xiu; Bao, Han; Liu, Ji-Ting; Zhuang, Fei; Li, Haipeng; Yao, Qing; Jiang, Zong‐Lai; Qi, Ying‐Xin

doi:10.1016/j.medntd.2021.100103

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, microvesicles (MVs) are nanosized particles - 50–1,000 nm in diameter - generated through cell membrane budding after agonist activation, shear/physical stress, or oxidative stress, and may contain organelles proteins –such as those from the endoplasmic reticulum, Golgi, mitochondria and nucleus—( Boilard, 2018 ; Agrahari et al, 2019 ; Bodega et al, 2019 ). MVs also participate in intercellular communication, modulating several biological functions ( Zi-Tong et al, 2022 ). It is important to highlight that since analytical techniques do not differentiate between exosomes and MVs due to their range overlapping, the International Society for Extracellular Vesicles recommends using the term small EVs (sEVs) instead ( Witwer and Théry, 2019 ).…”

Section: Extracellular Vesicles As a New Paradigm For Cell-free Therapymentioning

confidence: 99%

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Sanmartin

Borzone

Giorello

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide, with 10.0 million cancer deaths in 2020. Despite advances in targeted therapies, some pharmacological drawbacks associated with anticancer chemo and immunotherapeutic agents include high toxicities, low bioavailability, and drug resistance. In recent years, extracellular vesicles emerged as a new promising platform for drug delivery, with the advantage of their inherent biocompatibility and specific targeting compared to artificial nanocarriers, such as liposomes. Particularly, mesenchymal stem/stromal cells were proposed as a source of extracellular vesicles for cancer therapy because of their intrinsic properties: high in vitro self-renewal and proliferation, regenerative and immunomodulatory capacities, and secretion of extracellular vesicles that mediate most of their paracrine functions. Moreover, extracellular vesicles are static and safer in comparison with mesenchymal stem/stromal cells, which can undergo genetic/epigenetic or phenotypic changes after their administration to patients. In this review, we summarize currently reported information regarding mesenchymal stem/stromal cell-derived extracellular vesicles, their proper isolation and purification techniques - from either naive or engineered mesenchymal stem/stromal cells - for their application in cancer therapy, as well as available downstream modification methods to improve their therapeutic properties. Additionally, we discuss the challenges associated with extracellular vesicles for cancer therapy, and we review some preclinical and clinical data available in the literature.

show abstract

Section: Extracellular Vesicles As a New Paradigm For Cell-free Therapymentioning

confidence: 99%

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Sanmartin

Borzone

Giorello

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Platelet-derived microvesicles deliver miR-30e and promote VSMC apoptosis after balloon injury

Cited by 1 publication

References 35 publications

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Contact Info

Product

Resources

About